Cancer-Specific Gene Detection
Creative Biolabs is a leading service company with a robust and standardized sequencing platform supporting cancer research. With over a decade of experience and state-of-the-art sequencing platforms, we offer a full range of cancer gene detection services to support cancer research including cancer pathogenesis and treatment strategy development. Over the past decades, our specialized and dedicated scientists have been developed a series of proprietary cancer-specific gene panels which enable to detection of multiple gene mutations associated with tumorigenesis and drug medicine, greatly facilitating your cancer research.
Our cancer-specific gene detection services include but are not limited to:
Classification | Description | Method | Cycle |
---|---|---|---|
Lung Cancer Gene Panel | Lung Cancer 56 Genes Detection (MSI) | NGS | 2~3 Weeks |
Lung Cancer 14 Genes Detection | NGS | 2~3 Weeks | |
Dynamic Monitoring of Lung Cancer | NGS | 2~3 Weeks | |
Breast Cancer Gene Panel | Breast Cancer 62 Genes Detection (MSI) | NGS | 2~3 Weeks |
Breast Cancer 21 Genes Detection | RT-PCR | 2~3 Weeks | |
BRCA1/2 Gene Detection | NGS | 2~3 Weeks | |
Colorectal Cancer Gene Panel | Colorectal Cancer 43 Genes Detection (MSI) | NGS | 2~3 Weeks |
Colorectal Cancer 4 Genes Detection | NGS | 2~3 Weeks | |
Dynamic Monitoring of Colorectal Cancer | NGS | 2~3 Weeks | |
Gastric Cancer Gene Panel | Gastric Cancer 40 Genes Detection (MSI) | NGS | 2~3 Weeks |
Gastrointestinal stromal tumor (GIST) Gene Panel | GIST 25 Genes Detection | NGS | 2~3 Weeks |
Melanoma Gene Panel | Melanoma 25 Genes Detection | NGS | 2~3 Weeks |
Pancreatic Cancer Gene Panel | Pancreatic Cancer 48 Genes Detection (MSI) | NGS | 2~3 Weeks |
Ovarian Cancer/Endometrial Cancer Gene Panel | Ovarian Cancer 62 Genes Detection (MSI) | NGS | 2~3 Weeks |
Endometrial Cancer 99 Genes Detection (MSI) | NGS | 2~3 Weeks | |
BRCA1/2 Gene Mutation Detection | NGS | 2~3 Weeks | |
Bladder Cancer Gene Panel | Bladder Cancer 60 Genes Detection (MSI) | NGS | 2~3 Weeks |
Prostate Adenocarcinoma Gene Panel | Prostate Adenocarcinoma 48 Genes Detection (MSI) | NGS | 2~3 Weeks |
Thyroid Cancer Gene Panel | Thyroid Cancer 65 Genes Detection | NGS | 2~3 Weeks |
Liver and Bile Tumor Gene Panel | Liver and Bile Tumor 72 Genes Detection (MSI) | NGS | 2~3 Weeks |
Lymphoma Gene Panel | Non-hodgkin Lymphoma 105 Genes Detection | NGS | 2~3 Weeks |
Leukemia Gene Panel | Myeloid Neoplasms 58 Genes Detection | NGS | 2~3 Weeks |
Bone Marrow Proliferative Tumor 3 Genes Detection | NGS | 2~3 Weeks | |
MSI Detection | MSI Detection | NGS | 2~3 Weeks |
Single Gene Detection | EGFR Gene Mutation Detection | NGS | 2~3 Weeks |
KRAS Gene Mutation Detection | NGS | 2~3 Weeks | |
BRAF V600E Mutation Detection | NGS | 2~3 Weeks | |
EGFR T790M Mutation Detection | NGS | 2~3 Weeks | |
EGFR/ALK/ROS1 Gene Detection | NGS | 2~3 Weeks | |
KRAS/NRAS/BRAF Gene Detection | NGS | 2~3 Weeks |
Sample Requirement
Sample Type | Amount | Sampling Requirements | Transportation |
---|---|---|---|
Fresh tissue sample |
Surgery: ≥0.5cm3; Puncture: >2 needles, length>1 cm |
Tumor proportion is more than 50%, and the minimum was 20%. Central tissue was taken as far as possible, and the necrotic tissue proportion was less than 10%. | Dry ice transport |
Paraffin block | 1-2 blocks |
Tumor proportion is more than 50%, and the minimum was 20%. Central tissue was taken as far as possible, and the necrotic tissue proportion was less than 10%. Send at least one HE stained film. Shelf life is within one year |
Transport at room temperature |
Peripheral blood (ctDNA) | 10 mL | No severe coagulation or hemolysis. | BCT Blood collection tube; Dry ice transport |
Peripheral blood | 3-5 mL | No coagulation or hemolysis. | EDTA anticoagulation tube; Dry ice transport |
Highlights
- Advanced sequencing technologies
- Rich experience in cancer gene detection
- An efficient standard workflow
- Customizable cancer gene detection panel
- Fastest turnaround time
As a reliable sequencing company, Creative Biolabs is committed and proud to be part of this rewarding challenge by offering support to NGS-based cancer research services for our clients. If you are interested in our services, please feel free to contact us for more details.